Hepaclin5 gm/10 ml

Hepaclin is an amino acid combination used primarily to lower elevated blood ammonia levels and manage its consequences in patients with liver disease.

Established / guideline-supported uses

• Hepatic encephalopathy (acute and chronic, including latent/minimal hepatic encephalopathy): Hepaclin is used as an adjunct, together with standard measures such as lactulose, dietary protein adjustment, and correction of precipitating factors, to reduce blood ammonia and improve mental status.
• Hyperammonemia associated with liver disease: used to reduce elevated ammonia levels resulting from impaired hepatic urea-cycle function.

Commonly used adjunct/supportive indications (regional practice, variable evidence quality)

• Liver cirrhosis with impaired liver function
• Fatty liver disease and alcoholic liver damage, as supportive therapy
• Supportive recovery after acute viral hepatitis

Hepaclin is not a substitute for treatment of the underlying liver disease and is not approved as a stand-alone cure for cirrhosis or hepatitis; it is used as adjunctive therapy alongside standard hepatology care.

Each unit of L-Ornithine L-Aspartate contains a stable salt combination of two naturally occurring (endogenous) amino acids: L-ornithine and L-aspartate, combined in a 1:1 molar ratio.

L-Ornithine L-Aspartate is available in multiple dosage forms, including oral granules/powder sachets (for oral solution), film-coated tablets, and concentrate for intravenous infusion, depending on the manufacturer and clinical setting.

Hepaclin is a combination of two endogenous (naturally occurring in the body) amino acids, ornithine and aspartate, marketed as an ammonia-lowering (ammonia-detoxifying) agent for use in liver disease.

Both amino acids are natural intermediates of the urea cycle and related metabolic pathways. By supplying additional ornithine and aspartate, Hepaclin supports the body's own capacity to convert toxic ammonia into non-toxic compounds, which is particularly relevant in patients whose liver function is impaired.

Hepaclin is widely used across Asia and Europe (including in Bangladesh) as an adjunct treatment for hepatic encephalopathy and other hyperammonemia-related conditions, and is available as oral sachets, tablets, and intravenous infusion concentrate.

Hepaclin belongs to the class of ammonia-detoxifying agents / hepatoprotective amino acid combinations, used in the management of hepatic encephalopathy and hyperammonemia associated with liver disease.

L-Ornithine L-Aspartate acts by supplying substrates for two complementary ammonia-detoxification pathways in the body:

• L-Ornithine is a key intermediate of the hepatic urea cycle. It stimulates the activity of the urea-cycle enzymes carbamoyl phosphate synthetase and ornithine carbamoyltransferase, increasing conversion of ammonia into urea, which is then excreted by the kidneys.
• L-Aspartate is taken up mainly by skeletal muscle and brain (periportal and perivenous processes), where it contributes to the synthesis of glutamine from ammonia via glutamine synthetase, providing an alternative ammonia-detoxification route, and also enters the citric acid cycle to support cellular energy (ATP) production in hepatocytes, aiding hepatocyte regeneration.

Both amino acids are rapidly absorbed and metabolized via normal amino acid metabolic pathways; they are not extensively protein-bound and do not require hepatic biotransformation to be active, which makes L-Ornithine L-Aspartate suitable for use even when liver metabolic capacity is reduced.

• Oral sachets/granules: Dissolve the full contents of one sachet of Hepaclin in a glass of water, juice, or other fluid and drink immediately, preferably with or after a meal.
• Tablets: Swallow whole with water, preferably after meals.
• IV infusion: Must be diluted in a compatible infusion fluid (e.g., normal saline or dextrose solution) and administered as a slow intravenous infusion under medical supervision; never give as an undiluted rapid injection. Infusion rate should not exceed approximately 5 g/hour.

No clinically significant drug–drug interactions with Hepaclin are well established in the literature. Because Hepaclin is an amino acid preparation processed through normal amino acid and ammonia metabolic pathways, it has low potential for interaction with most co-administered medications.

As a general precaution, inform the physician of all other medicines, supplements, and herbal products being used before starting Hepaclin, particularly other ammonia-lowering agents (e.g., lactulose, rifaximin) so that therapy can be coordinated, and other amino acid/protein-containing infusions or supplements.

Hepaclin is generally well tolerated. Reported side effects are usually mild and transient:

• Common: Nausea and vomiting, especially with rapid intravenous infusion — reducing the infusion rate typically resolves this.
• Less common: Mild gastrointestinal discomfort, abdominal pain, or diarrhea with oral use.
• Rare: Hypersensitivity-type skin reactions (rash, itching).

If severe or persistent side effects occur, discontinue Hepaclin and consult a physician.

Data on the use of Hepaclin during pregnancy and breastfeeding are limited. As a precaution, Hepaclin should be used during pregnancy and lactation only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus or infant. A physician should be consulted before use in these situations, and use should be under direct medical supervision.

Renal function should be monitored regularly (serum urea/creatinine) in patients receiving Hepaclin, particularly those with pre-existing renal impairment, because Hepaclin increases nitrogenous (urea) load that requires renal excretion — see Contraindications for severe renal impairment.

Use with caution and slow the infusion rate if nausea or vomiting occurs during intravenous administration (see Side Effects).

Hepaclin is an adjunct to, not a replacement for, standard management of the underlying liver disease (e.g., lactulose, protein restriction where advised, and treatment of precipitating factors of hepatic encephalopathy such as infection, gastrointestinal bleeding, or electrolyte disturbance).

Use in pregnancy and lactation only as advised by a physician (see Pregnancy and Lactation).

Specific data on Hepaclin overdose in humans are limited. Excessive doses, particularly by rapid intravenous infusion, may be expected to worsen gastrointestinal symptoms such as nausea and vomiting, and could theoretically increase nitrogenous load in patients with reduced renal function.

If an overdose of Hepaclin is suspected, stop the infusion/medicine and seek immediate medical attention, or contact a physician, hospital emergency department, or poison control center. Treatment is supportive and symptomatic, guided by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use IV ampoules that show discoloration or particulate matter.

Renal impairment

Hepaclin is contraindicated in severe renal impairment/renal failure (see Contraindications). In milder renal impairment, use with caution and monitor renal function.

Hepatic impairment

Hepaclin is specifically used in patients with hepatic impairment (e.g., cirrhosis, hepatic encephalopathy) as part of adjunct therapy; no dose adjustment beyond standard indication-based dosing is established, but treatment should be supervised by a physician managing the liver disease.

Elderly

No specific dose adjustment is established for elderly patients, but renal function should be assessed before and during use given the higher background prevalence of reduced renal function in this group.

Pediatric use

See Pediatric Uses.

Duration of Hepaclin therapy depends on the indication and clinical response and should be determined by the treating physician. In acute hepatic encephalopathy, intravenous therapy is typically continued until clinical and biochemical (ammonia level) improvement, often several days, sometimes followed by a course of oral maintenance therapy. In chronic liver disease, oral Hepaclin may be used for longer maintenance periods as advised by the physician, with periodic reassessment of ongoing need.

Amino acid combination; ammonia-detoxifying / hepatoprotective agent.

L-Ornithine L-Aspartate works through two complementary metabolic routes to reduce blood ammonia:

• Ornithine activates the hepatic urea cycle enzymes, increasing conversion of ammonia to urea for renal excretion.
• Aspartate is used as a substrate for glutamine synthesis (an alternative ammonia-fixing pathway in muscle and brain) and supports hepatocellular energy metabolism via the citric acid cycle, aiding liver cell function and regeneration.

The net effect is a reduction in circulating ammonia and improvement in ammonia-related symptoms such as those seen in hepatic encephalopathy.

The safety and efficacy of Hepaclin in children have not been well established through controlled pediatric trials, and no standard pediatric dosing regimen is established in official labeling. Hepaclin should be used in children only under direct physician supervision, when the potential benefit is judged by the treating pediatrician/hepatologist to outweigh the uncertainties, such as in pediatric hyperammonemia or hepatic encephalopathy managed in a specialist setting.